{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T20:56:39Z","timestamp":1789764999380,"version":"4.0.1"},"reference-count":47,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2024,3,8]],"date-time":"2024-03-08T00:00:00Z","timestamp":1709856000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,3,8]],"date-time":"2024-03-08T00:00:00Z","timestamp":1709856000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100018778","name":"Al-Azhar University","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100018778","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Acta Neurol Belg"],"published-print":{"date-parts":[[2024,4]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Multiple sclerosis (MS) is a chronic inflammatory, immune-mediated disease affecting the central nervous system. Natalizumab, an FDA-approved monoclonal antibody for MS, has been explored for its off-label extended interval dosing (EID), suggesting a potential reduction in the risk of progressive multifocal leukoencephalopathy (PML) compared to standard interval dosing (SID). Our objective was to assess the efficacy and safety of EID in comparison to SID for natalizumab treatment in patients with MS.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>We searched PubMed, Embase, WOS, Scopus, Ovid, Science Direct, Clinical trials.gov, and Cochrane Library. Our assessed outcomes were clinical relapses, MRI activity, change in expanded disability status scale [EDSS], and the risk of PML. The EID group was defined as 5 to 8\u00a0weeks [EID (Q5-8W)]. The analysis was conducted using RevMan ver. 5.4. The effect estimates were presented as a risk ratio [RR] or mean difference with 95% confidence intervals [CI] using SID group as the reference for comparisons.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>Fourteen studies met our inclusion criteria: 2 RCTs, 1 switched single-arm trial, and 12 observational studies. No significant differences were found in all efficacy outcomes of interest. Risk of clinical relapses [RR\u2009=\u20090.90, (95%CI 0.80, 1.02)], risk of new or newly enlarging T2 hyperintense MRI lesions [RR\u2009=\u20090.78, (95%CI 0.59, 1.04)], risk gadolinium enhancing lesions [RR\u2009=\u20091.30, (95%CI 0.98, 1.72)], change in EDSS [MD\u2009=\u20090.09 (95%CI \u2212\u00a00.57, 0.76)], risk of PML [RR\u2009=\u20091.09, 95%CI (0.24, 4.94)].<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusion<\/jats:title>\n                <jats:p>In summary, our meta-analysis indicates that natalizumab maintains its effectiveness under extended interval dosing [up to 8\u00a0weeks], presenting comparable risks for clinical relapses, MRI lesions, EDSS, and PML. Caution is advised given study limitations and heterogeneity. Robust conclusions necessitate well-designed high-quality prospective studies.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1007\/s13760-024-02480-6","type":"journal-article","created":{"date-parts":[[2024,3,8]],"date-time":"2024-03-08T09:02:33Z","timestamp":1709888553000},"page":"407-417","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":12,"title":["Safety and efficacy of extended versus standard interval dosing of natalizumab in multiple sclerosis patients: a systematic review and meta-analysis"],"prefix":"10.1007","volume":"124","author":[{"given":"Eslam Mohammed","family":"Rabea","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohamed Mohamed","family":"Belal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abdelrahman H.","family":"Hafez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ashraf Hassan","family":"Elbanna","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mahmoud Ahmed","family":"Khalifa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anas Zakarya","family":"Nourelden","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nada H.","family":"Mahmoud","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0904-9153","authenticated-orcid":false,"given":"Mohamed Sayed","family":"Zaazouee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,3,8]]},"reference":[{"key":"2480_CR1","volume-title":"Multiple sclerosis","author":"D Tafti","year":"2022","unstructured":"Tafti D, Ehsan M, Xixis KL (2022) Multiple sclerosis. StatPearls Publishing LLC, Treasure Island"},{"issue":"4","key":"2480_CR2","doi-asserted-by":"publisher","first-page":"742","DOI":"10.1016\/j.neuron.2018.01.021","volume":"97","author":"C Baecher-Allan","year":"2018","unstructured":"Baecher-Allan C, Kaskow BJ, Weiner HL (2018) Multiple sclerosis: mechanisms and immunotherapy. Neuron 97(4):742\u2013768","journal-title":"Neuron"},{"key":"2480_CR3","unstructured":"Number of people with MS|Atlas of MS. www.atlasofms.org. https:\/\/www.atlasofms.org\/map\/global\/epidemiology\/number-of-people-with-ms#:~:text=The%20data%20shows%20that%20the%20number%20of%20people. Accessed 23 Jul 2023"},{"issue":"7","key":"2480_CR4","doi-asserted-by":"publisher","first-page":"608","DOI":"10.1016\/S1474-4422(22)00143-0","volume":"21","author":"JF Foley","year":"2022","unstructured":"Foley JF, Defer G, Ryerson LZ, Cohen JA, Arnold DL, Butzkueven H et al (2022) Comparison of switching to 6-week dosing of natalizumab versus continuing with 4-week dosing in patients with relapsing-remitting multiple sclerosis [NOVA]: a randomised, controlled, open-label, phase 3b trial. Lancet Neurol 21(7):608\u2013619","journal-title":"Lancet Neurol"},{"issue":"7","key":"2480_CR5","doi-asserted-by":"publisher","first-page":"78","DOI":"10.3390\/brainsci7070078","volume":"7","author":"N Dargahi","year":"2017","unstructured":"Dargahi N, Katsara M, Tselios T, Androutsou ME, de Courten M, Matsoukas J et al (2017) Multiple sclerosis: immunopathology and treatment update. Brain Sci 7(7):78","journal-title":"Brain Sci"},{"key":"2480_CR6","volume-title":"Natalizumab","author":"A Babaesfahani","year":"2022","unstructured":"Babaesfahani A, Khanna NR, Kuns B (2022) Natalizumab. StatPearls Publishing, Treasure Island"},{"issue":"4","key":"2480_CR7","doi-asserted-by":"publisher","first-page":"521","DOI":"10.1007\/s10072-012-1088-8","volume":"34","author":"R Lanzillo","year":"2013","unstructured":"Lanzillo R, Bonavita S, Quarantelli M, Vacca G, Lus G, Amato L et al (2013) Natalizumab is effective in multiple sclerosis patients switching from other disease modifying therapies in clinical practice. Neurol Sci 34(4):521\u2013528","journal-title":"Neurol Sci"},{"issue":"5","key":"2480_CR8","doi-asserted-by":"publisher","first-page":"883","DOI":"10.1136\/jim-2016-000339","volume":"65","author":"DL Vargas","year":"2017","unstructured":"Vargas DL, Tyor WR (2017) Update on disease-modifying therapies for multiple sclerosis. J Investig Med 65(5):883\u2013891","journal-title":"J Investig Med"},{"issue":"9","key":"2480_CR9","doi-asserted-by":"publisher","first-page":"899","DOI":"10.1056\/NEJMoa044397","volume":"354","author":"CH Polman","year":"2006","unstructured":"Polman CH, O\u2019Connor PW, Havrdova E, Hutchinson M, Kappos L, Miller DH et al (2006) A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis. N Engl J Med 354(9):899\u2013910","journal-title":"N Engl J Med"},{"issue":"3","key":"2480_CR10","doi-asserted-by":"publisher","first-page":"254","DOI":"10.1016\/S1474-4422(09)70021-3","volume":"8","author":"E Havrdova","year":"2009","unstructured":"Havrdova E, Galetta S, Hutchinson M, Stefoski D, Bates D, Polman CH et al (2009) Effect of natalizumab on clinical and radiological disease activity in multiple sclerosis: a retrospective analysis of the Natalizumab Safety and Efficacy in Relapsing-Remitting Multiple Sclerosis [AFFIRM] study. Lancet Neurol 8(3):254\u2013260","journal-title":"Lancet Neurol"},{"issue":"2","key":"2480_CR11","doi-asserted-by":"publisher","first-page":"284","DOI":"10.1007\/s00415-016-8343-5","volume":"264","author":"L Prosperini","year":"2017","unstructured":"Prosperini L, Sacc\u00e0 F, Cordioli C, Cortese A, Buttari F, Pontecorvo S et al (2017) Real-world effectiveness of natalizumab and fingolimod compared with self-injectable drugs in non-responders and in treatment-na\u00efve patients with multiple sclerosis. J Neurol 264(2):284\u2013294","journal-title":"J Neurol"},{"issue":"11","key":"2480_CR12","doi-asserted-by":"publisher","first-page":"925","DOI":"10.1016\/S1474-4422(17)30282-X","volume":"16","author":"PR Ho","year":"2017","unstructured":"Ho PR, Koendgen H, Campbell N, Haddock B, Richman S, Chang I (2017) Risk of natalizumab-associated progressive multifocal leukoencephalopathy in patients with multiple sclerosis: a retrospective analysis of data from four clinical studies. Lancet Neurol 16(11):925\u2013933","journal-title":"Lancet Neurol"},{"issue":"20","key":"2480_CR13","doi-asserted-by":"publisher","first-page":"1870","DOI":"10.1056\/NEJMoa1107829","volume":"366","author":"G Bloomgren","year":"2012","unstructured":"Bloomgren G, Richman S, Hotermans C, Subramanyam M, Goelz S, Natarajan A et al (2012) Risk of natalizumab-associated progressive multifocal leukoencephalopathy. N Engl J Med 366(20):1870\u20131880","journal-title":"N Engl J Med"},{"issue":"6","key":"2480_CR14","doi-asserted-by":"publisher","first-page":"805","DOI":"10.1177\/1352458517708464","volume":"24","author":"ZL Van Kempen","year":"2018","unstructured":"Van Kempen ZL, Leurs CE, Witte BI, de Vries A, Wattjes MP, Rispens T et al (2018) The majority of natalizumab-treated MS patients have high natalizumab concentrations at time of re-dosing. Mult Scler 24(6):805\u2013810","journal-title":"Mult Scler"},{"issue":"3","key":"2480_CR15","doi-asserted-by":"publisher","first-page":"392","DOI":"10.1002\/ana.22074","volume":"68","author":"J Killestein","year":"2010","unstructured":"Killestein J, Vennegoor A, Strijbis EM, Seewann A, van Oosten BW, Uitdehaag BM et al (2010) Natalizumab drug holiday in multiple sclerosis: poorly tolerated. Ann Neurol 68(3):392\u2013395","journal-title":"Ann Neurol"},{"issue":"9","key":"2480_CR16","doi-asserted-by":"publisher","first-page":"1337","DOI":"10.1177\/1352458512439438","volume":"18","author":"LM Grimaldi","year":"2012","unstructured":"Grimaldi LM, Prosperini L, Vitello G, Borriello G, Fubelli F, Pozzilli C (2012) MRI-based analysis of the natalizumab therapeutic window in multiple sclerosis. Mult Scler 18(9):1337\u20131339","journal-title":"Mult Scler"},{"issue":"15","key":"2480_CR17","doi-asserted-by":"publisher","first-page":"e1452","DOI":"10.1212\/WNL.0000000000008243","volume":"93","author":"LZ Ryerson","year":"2019","unstructured":"Ryerson LZ, Foley J, Chang I, Kister I, Cutter G, Metzger RR et al (2019) Risk of natalizumab-associated PML in patients with MS is reduced with extended interval dosing. Neurology 93(15):e1452\u2013e1462","journal-title":"Neurology"},{"key":"2480_CR18","doi-asserted-by":"publisher","first-page":"716548","DOI":"10.3389\/fneur.2021.716548","volume":"12","author":"JM Serra L\u00f3pez-Matencio","year":"2021","unstructured":"Serra L\u00f3pez-Matencio JM, P\u00e9rez Garc\u00eda Y, Meca-Lallana V, Ju\u00e1rez-S\u00e1nchez R, Ursa A, Vega-Piris L et al (2021) Evaluation of natalizumab pharmacokinetics and pharmacodynamics: toward individualized doses. Front Neurol 12:716548","journal-title":"Front Neurol"},{"issue":"2","key":"2480_CR19","doi-asserted-by":"publisher","first-page":"e672","DOI":"10.1212\/NXI.0000000000000672","volume":"7","author":"L Zhovtis Ryerson","year":"2020","unstructured":"Zhovtis Ryerson L, Li X, Goldberg JD, Hoyt T, Christensen A, Metzger RR et al (2020) Pharmacodynamics of natalizumab extended interval dosing in MS. Neurol Neuroimmunol Neuroinflamm 7(2):e672","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"key":"2480_CR20","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1016\/j.msard.2019.03.017","volume":"31","author":"JF Foley","year":"2019","unstructured":"Foley JF, Goelz S, Hoyt T, Christensen A, Metzger RR (2019) Evaluation of natalizumab pharmacokinetics and pharmacodynamics with standard and extended interval dosing. Mult Scler Relat Disord 31:65\u201371","journal-title":"Mult Scler Relat Disord"},{"issue":"14","key":"2480_CR21","doi-asserted-by":"publisher","first-page":"2240","DOI":"10.1177\/13524585211003020","volume":"27","author":"M Trojano","year":"2021","unstructured":"Trojano M, Rami\u00f3-Torrent\u00e0 L, Grimaldi LM, Lubetzki C, Schippling S, Evans KC et al (2021) A randomized study of natalizumab dosing regimens for relapsing-remitting multiple sclerosis. Mult Scler 27(14):2240\u20132253","journal-title":"Mult Scler"},{"key":"2480_CR22","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1016\/j.msard.2018.06.015","volume":"24","author":"BI Yamout","year":"2018","unstructured":"Yamout BI, Sahraian MA, Ayoubi NE, Tamim H, Nicolas J, Khoury SJ et al (2018) Efficacy and safety of natalizumab extended interval dosing. Mult Scler Relat Disord 24:113\u2013116","journal-title":"Mult Scler Relat Disord"},{"key":"2480_CR23","doi-asserted-by":"publisher","first-page":"175628642110424","DOI":"10.1177\/17562864211042458","volume":"14","author":"H Butzkueven","year":"2021","unstructured":"Butzkueven H, Kappos L, Spelman T, Trojano M, Wiendl H, Su R et al (2021) No evidence for loss of natalizumab effectiveness with every-6-week dosing: a propensity score-matched comparison with every-4-week dosing in patients enrolled in the Tysabri Observational Program [TOP]. Ther Adv Neurol Disord 14:17562864211042458","journal-title":"Ther Adv Neurol Disord"},{"key":"2480_CR24","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.n71","volume":"372","author":"MJ Page","year":"2021","unstructured":"Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD et al (2021) The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ 372:n71","journal-title":"BMJ"},{"key":"2480_CR25","unstructured":"Higgins JPT, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, et al. (2022) Cochrane handbook for systematic reviews of interventions version 6.3 Cochrane. www.training.cochrane.org\/handbook. Accessed 15 May 2023"},{"issue":"1","key":"2480_CR26","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1186\/s13643-016-0384-4","volume":"5","author":"M Ouzzani","year":"2016","unstructured":"Ouzzani M, Hammady H, Fedorowicz Z, Elmagarmid A (2016) Rayyan\u2014a web and mobile app for systematic reviews. Syst Rev 5(1):210","journal-title":"Syst Rev"},{"issue":"7414","key":"2480_CR27","doi-asserted-by":"publisher","first-page":"557","DOI":"10.1136\/bmj.327.7414.557","volume":"327","author":"JP Higgins","year":"2003","unstructured":"Higgins JP, Thompson SG, Deeks JJ, Altman DG (2003) Measuring inconsistency in meta-analyses. BMJ 327(7414):557\u2013560","journal-title":"BMJ"},{"issue":"2","key":"2480_CR28","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1016\/j.cct.2006.04.004","volume":"28","author":"R DerSimonian","year":"2007","unstructured":"DerSimonian R, Kacker R (2007) Random-effects model for meta-analysis of clinical trials: an update. Contemp Clin Trials 28(2):105\u2013114","journal-title":"Contemp Clin Trials"},{"issue":"7650","key":"2480_CR29","doi-asserted-by":"publisher","first-page":"924","DOI":"10.1136\/bmj.39489.470347.AD","volume":"336","author":"GH Guyatt","year":"2008","unstructured":"Guyatt GH, Oxman AD, Vist GE, Kunz R, Falck-Ytter Y, Alonso-Coello P et al (2008) GRADE: an emerging consensus on rating quality of evidence and strength of recommendations. BMJ 336(7650):924\u2013926","journal-title":"BMJ"},{"key":"2480_CR30","unstructured":"NIH (2022) Study Quality Assessment Tools|NHLBI. https:\/\/www.nhlbi.nih.gov\/health-topics\/study-quality-assessment-tools. Accessed 7 Jul 2023"},{"issue":"9","key":"2480_CR31","doi-asserted-by":"publisher","first-page":"603","DOI":"10.1007\/s10654-010-9491-z","volume":"25","author":"A Stang","year":"2010","unstructured":"Stang A (2010) Critical evaluation of the Newcastle-Ottawa scale for the assessment of the quality of nonrandomized studies in meta-analyses. Eur J Epidemiol 25(9):603\u2013605","journal-title":"Eur J Epidemiol"},{"key":"2480_CR32","doi-asserted-by":"publisher","first-page":"103480","DOI":"10.1016\/j.msard.2021.103480","volume":"58","author":"LZ Ryerson","year":"2022","unstructured":"Ryerson LZ, Naismith RT, Krupp LB, Charvet LE, Liao S, Fisher E et al (2022) No difference in radiologic outcomes for natalizumab patients treated with extended interval dosing compared with standard interval dosing: real-world evidence from MS PATHS. Mult Scler Relat Disord 58:103480","journal-title":"Mult Scler Relat Disord"},{"issue":"5","key":"2480_CR33","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1177\/1756285614540224","volume":"7","author":"R Bomprezzi","year":"2014","unstructured":"Bomprezzi R, Pawate S (2014) Extended interval dosing of natalizumab: a two-center, 7-year experience. Ther Adv Neurol Disord 7(5):227\u2013231","journal-title":"Ther Adv Neurol Disord"},{"issue":"12","key":"2480_CR34","doi-asserted-by":"publisher","first-page":"1297","DOI":"10.1136\/jnnp-2020-323472","volume":"91","author":"CG Chisari","year":"2020","unstructured":"Chisari CG, Grimaldi LM, Salemi G, Ragonese P, Iaffaldano P, Bonavita S et al (2020) Clinical effectiveness of different natalizumab interval dosing schedules in a large Italian population of patients with multiple sclerosis. J Neurol Neurosurg Psychiatry 91(12):1297\u20131303","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"2480_CR35","doi-asserted-by":"publisher","first-page":"117385","DOI":"10.1016\/j.jns.2021.117385","volume":"424","author":"SF De Mercanti","year":"2021","unstructured":"De Mercanti SF, Signori A, Cordioli C, Signoriello E, Lus G, Bonavita S et al (2021) MRI activity and extended interval of Natalizumab dosing regimen: a multicentre Italian study. J Neurol Sci 424:117385","journal-title":"J Neurol Sci"},{"key":"2480_CR36","doi-asserted-by":"publisher","first-page":"614715","DOI":"10.3389\/fimmu.2021.614715","volume":"12","author":"J Riancho","year":"2021","unstructured":"Riancho J, Setien S, de la Torre JRS, Torres-Barquin M, Misiego M, P\u00e9rez JL et al (2021) Does extended interval dosing natalizumab preserve effectiveness in multiple sclerosis? A 7 year-retrospective observational study. Front Immunol 12:614715","journal-title":"Front Immunol"},{"issue":"8","key":"2480_CR37","doi-asserted-by":"publisher","first-page":"885","DOI":"10.1136\/jnnp-2015-312940","volume":"87","author":"LZ Ryerson","year":"2016","unstructured":"Ryerson LZ, Frohman TC, Foley J, Kister I, Weinstock-Guttman B, Tornatore C et al (2016) Extended interval dosing of natalizumab in multiple sclerosis. J Neurol Neurosurg Psychiatry 87(8):885\u2013889","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"6","key":"2480_CR38","first-page":"e745","volume":"95","author":"ZLE Van Kempen","year":"2020","unstructured":"Van Kempen ZLE, Hoogervorst ELJ, Wattjes MP, Kalkers NF, Mostert JP, Lissenberg-Witte BI et al (2020) Personalized extended interval dosing of natalizumab in MS: a prospective multicenter trial. Neurology 95(6):e745\u2013e754","journal-title":"Neurology"},{"key":"2480_CR39","doi-asserted-by":"publisher","first-page":"120689","DOI":"10.1016\/j.jns.2023.120689","volume":"450","author":"L Jeantin","year":"2023","unstructured":"Jeantin L, de la Motte MB, Deschamps R, Gueguen A, Gout O, Lecler A et al (2023) Natalizumab extended-interval dosing in a real-life setting. J Neurol Sci 450:120689","journal-title":"J Neurol Sci"},{"issue":"2","key":"2480_CR40","doi-asserted-by":"publisher","first-page":"529","DOI":"10.1007\/s40120-023-00440-5","volume":"12","author":"J Pelle","year":"2023","unstructured":"Pelle J, Briant AR, Branger P, Derache N, Arnaud C, Lebrun-Frenay C et al (2023) Real-world effectiveness of natalizumab extended interval dosing in a French cohort. Neurol Ther 12(2):529\u2013542","journal-title":"Neurol Ther"},{"issue":"1","key":"2480_CR41","doi-asserted-by":"publisher","first-page":"200","DOI":"10.1007\/s13311-019-00776-7","volume":"17","author":"M Clerico","year":"2020","unstructured":"Clerico M, De Mercanti SF, Signori A, Iudicello M, Cordioli C, Signoriello E et al (2020) Extending the interval of natalizumab dosing: is efficacy preserved? Neurotherapeutics 17(1):200\u2013207","journal-title":"Neurotherapeutics"},{"issue":"4","key":"2480_CR42","doi-asserted-by":"publisher","first-page":"375","DOI":"10.1056\/NEJMoa051847","volume":"353","author":"A Langer-Gould","year":"2005","unstructured":"Langer-Gould A, Atlas SW, Green AJ, Bollen AW, Pelletier D (2005) Progressive multifocal leukoencephalopathy in a patient treated with natalizumab. N Engl J Med 353(4):375\u2013381","journal-title":"N Engl J Med"},{"issue":"3","key":"2480_CR43","doi-asserted-by":"publisher","first-page":"e12","DOI":"10.1212\/CPJ.0000000000000457","volume":"8","author":"LE Baldassari","year":"2018","unstructured":"Baldassari LE, Jones SE, Clifford DB, Fox RJ (2018) Progressive multifocal leukoencephalopathy with extended natalizumab dosing. Neurol Clin Pract 8(3):e12\u2013e14","journal-title":"Neurol Clin Pract"},{"issue":"10","key":"2480_CR44","doi-asserted-by":"publisher","first-page":"2119","DOI":"10.1007\/s10072-019-03959-4","volume":"40","author":"C Scarpazza","year":"2019","unstructured":"Scarpazza C, De Rossi N, Tabiadon G, Turrini MV, Gerevini S, Capra R (2019) Four cases of natalizumab-related PML: a less severe course in extended interval dosing? Neurol Sci 40(10):2119\u20132124","journal-title":"Neurol Sci"},{"issue":"5","key":"2480_CR45","doi-asserted-by":"publisher","first-page":"399","DOI":"10.2217\/nmt.15.42","volume":"5","author":"JV Herv\u00e1s","year":"2015","unstructured":"Herv\u00e1s JV, Presas-Rodr\u00edguez S, Crespo-Cuevas AM, Canento T, Lozano-S\u00e1nchez M, Massuet-Vilamaj\u00f3 A et al (2015) Progressive multifocal leukoencephalopathy associated to natalizumab extended dosing regimen. Neurodegener Dis Manag 5(5):399\u2013402","journal-title":"Neurodegener Dis Manag"},{"issue":"13","key":"2480_CR46","doi-asserted-by":"publisher","first-page":"2070","DOI":"10.1177\/13524585221108080","volume":"28","author":"M Johnsson","year":"2022","unstructured":"Johnsson M, Farman HH, Blennow K, Zetterberg H, Malmestr\u00f6m C, Axelsson M et al (2022) No increase of serum neurofilament light in relapsing-remitting multiple sclerosis patients switching from standard to extended-interval dosing of natalizumab. Mult Scler 28(13):2070\u20132080","journal-title":"Mult Scler"},{"issue":"3","key":"2480_CR47","doi-asserted-by":"publisher","first-page":"109","DOI":"10.2217\/nmt-2021-0038","volume":"12","author":"M Moccia","year":"2022","unstructured":"Moccia M, Loperto I, Santoni L, Masera S, Affinito G, Carotenuto A et al (2022) Healthcare resource utilization and costs for extended interval dosing of natalizumab in multiple sclerosis. Neurodegener Dis Manag 12(3):109\u2013116","journal-title":"Neurodegener Dis Manag"}],"container-title":["Acta Neurologica Belgica"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13760-024-02480-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s13760-024-02480-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13760-024-02480-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,3,26]],"date-time":"2024-03-26T06:15:20Z","timestamp":1711433720000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s13760-024-02480-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,3,8]]},"references-count":47,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2024,4]]}},"alternative-id":["2480"],"URL":"https:\/\/doi.org\/10.1007\/s13760-024-02480-6","relation":{},"ISSN":["0300-9009","2240-2993"],"issn-type":[{"value":"0300-9009","type":"print"},{"value":"2240-2993","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,3,8]]},"assertion":[{"value":"19 September 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 January 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 March 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare that they have no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval and consent to participate"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}}]}}